Comparison of Risk of Preterm Labor Between Vaginal Progesterone And17-Alpha-Hydroxy-Progesterone Caproate in Women With Threatened Abortion: A Randomized Clinical Trial



Beigi A¹ ; Esmailzadeh A¹ ; Pirjani R¹ Show Affiliations
Source: International Journal of Fertility and Sterility Published:2016

Abstract

Background: Threatened miscarriage is a common complication in pregnancy that leads to adverse pregnancy outcomes such as preterm labor. This study aimed to compare the vaginal progesterone (Cyclogest) versus 17-alpha-hydroxyprogester-one caproate (Proluton) on preventing preterm labor in pregnant women with threatened abortion at less than 34 weeks’ gestational age. Materials and Methods: This balanced randomized, double-blind, single-center controlled clinical trial included 190 women with threatened abortion. They were then randomly allocated into Cyclogest (n=95) and 17-alpha-hydroxyprogesterone caproate (Proluton, n=95) groups. Interested outcome was preterm labor less than 34 weeks. The Pearson chi-square and Student’s t test were used to compare two groups. The data were analyzed by Stata software version 13. Results: The risks of preterm labor less than 34 weeks in Proluton and Cyclogest groups were 8.6 and 6.52%, respectively. There was no significant difference for risk of preterm labor less than 34 weeks [relative ratio (RR): 1.31, 95% confidence interval (CI): 0.47-3.66, P=0.59] between two groups. Conclusion: Risk of preterm labor in the vaginal progesterone group and 17-alpha-hy-droxyprogesterone caproate group in pregnant women with threatened abortion is the same (Registration Number: IRCT2014123120504N1). © 2016, Royan Institute (ACECR). All Rights Reserved.